Purpose
To determine the impact of uninterrupted use of warfarin on hand and wrist surgery.
Methods
This single-center, prospective cohort trial enrolled adult patients undergoing hand and wrist surgery. Between May 2009 and August 2014, 47 surgical patients on uninterrupted warfarin (50 procedures) were enrolled and matched as a group by age and procedure type to 48 surgical patients (50 procedures) who were not prescribed warfarin. Complications, defined as bleeding, infection, or wound dehiscence requiring reoperation, were recorded for each group. Surgical outcome measures comprised objective findings impacted by surgical site bleeding (i.e., ecchymosis extent, hematoma presence, 2-point discrimination) and standardized patient-rated assessments (QuickDASH, visual analog scales: pain and swelling). Data were collected preoperatively and at 2 and 4 weeks postoperatively. Statistical analyses contrasted complications and outcomes data between the patient groups.
Results
One procedure (2%, 95% CI:0–11%) in a patient taking warfarin was complicated by hematoma requiring reoperation secondary to an elevated postoperative International Normalized Ratio=5.4. There were no complications among controls (0%, 95%CI:0–7%). At 2 weeks postoperatively, patients on warfarin more frequently had hematomas (28% vs 10%) and demonstrated greater extent of ecchymosis from the surgical incision (50mm vs 19mm). At 4 weeks, no differences in hematoma presence or extent of ecchymosis existed between the groups. The incidence of transiently elevated 2-point discrimination was not different between the groups (10% warfarin, 6% controls). Visual analog scores for pain and swelling were not significantly different between the groups at any time. Differences in QuickDASH scores between the groups never exceeded a minimal clinically important difference.
Conclusions
Uninterrupted use of warfarin in patients undergoing surgery of the hand and wrist was associated with an infrequent risk of bleeding complication requiring reoperation. Increased rates of hematoma and ecchymosis in patients taking warfarin normalized by 4 weeks postoperatively.
Level of Evidence
II Therapeutic